Form 4: Tenaya Therapeutics Director, Karah Herdman Parschauer, Reports Stock Option Grant

Director Karah Herdman Parschauer reports the acquisition of stock options in Tenaya Therapeutics, Inc.

Summary

• Karah Herdman Parschauer, a director of Tenaya Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership.
• The report details the grant of stock options to Parschauer on October 18, 2024.
• Parschauer was granted options to purchase 34,000 shares of common stock at an exercise price of $2.04 per share.
• The options vest in full on May 31, 2025, or the day before the next annual meeting of stockholders after the grant date, subject to continued service.
• Following the transaction, Parschauer directly owns options for 34,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (34,000 shares) and the vesting schedule (full vesting in approximately 7 months) appear to be within the typical range for similar companies and roles.
• Companies like CRISPR Therapeutics and Beam Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates